JP2005506340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506340A5 JP2005506340A5 JP2003535542A JP2003535542A JP2005506340A5 JP 2005506340 A5 JP2005506340 A5 JP 2005506340A5 JP 2003535542 A JP2003535542 A JP 2003535542A JP 2003535542 A JP2003535542 A JP 2003535542A JP 2005506340 A5 JP2005506340 A5 JP 2005506340A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- targeted therapeutic
- igf
- amino acids
- targeted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 39
- 229940124597 therapeutic agent Drugs 0.000 claims 37
- 150000001413 amino acids Chemical class 0.000 claims 19
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 12
- 102000044162 human IGF1 Human genes 0.000 claims 12
- 230000008685 targeting Effects 0.000 claims 11
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 7
- 102000013275 Somatomedins Human genes 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 108010031792 IGF Type 2 Receptor Proteins 0.000 claims 3
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 3
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 3
- 230000008499 blood brain barrier function Effects 0.000 claims 3
- 210000001218 blood-brain barrier Anatomy 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 230000002132 lysosomal effect Effects 0.000 claims 3
- 210000003712 lysosome Anatomy 0.000 claims 3
- 230000001868 lysosomic effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 101001028831 Homo sapiens Cation-independent mannose-6-phosphate receptor Proteins 0.000 claims 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32965001P | 2001-10-16 | 2001-10-16 | |
| US10/136,841 US7396811B2 (en) | 2001-04-30 | 2002-04-30 | Subcellular targeting of therapeutic proteins |
| US10/136,639 US20030072761A1 (en) | 2001-10-16 | 2002-04-30 | Methods and compositions for targeting proteins across the blood brain barrier |
| US38445202P | 2002-05-29 | 2002-05-29 | |
| US38601902P | 2002-06-05 | 2002-06-05 | |
| US40881602P | 2002-09-06 | 2002-09-06 | |
| PCT/US2002/032968 WO2003032727A1 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009143436A Division JP2009203241A (ja) | 2001-10-16 | 2009-06-16 | 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506340A JP2005506340A (ja) | 2005-03-03 |
| JP2005506340A5 true JP2005506340A5 (enExample) | 2006-01-12 |
Family
ID=27558195
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003535542A Pending JP2005506340A (ja) | 2001-10-16 | 2002-10-16 | 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物 |
| JP2009143436A Pending JP2009203241A (ja) | 2001-10-16 | 2009-06-16 | 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009143436A Pending JP2009203241A (ja) | 2001-10-16 | 2009-06-16 | 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1446007A4 (enExample) |
| JP (2) | JP2005506340A (enExample) |
| AU (3) | AU2002362930A2 (enExample) |
| CA (1) | CA2463473A1 (enExample) |
| IL (1) | IL161352A0 (enExample) |
| WO (2) | WO2003032913A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158623A0 (en) | 2001-04-30 | 2004-05-12 | Symbiontics Inc | Subcellular targeting of therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| AU2002362930A2 (en) * | 2001-10-16 | 2003-04-28 | Zystor Therapeutics, Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| AU2003237314B2 (en) * | 2002-05-29 | 2010-03-04 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
| US20050244400A1 (en) * | 2004-02-10 | 2005-11-03 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| EP2997976A1 (en) | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| EP2234600B1 (en) * | 2007-12-21 | 2014-08-20 | F. Hoffmann-La Roche AG | Antibody formulation |
| HUE034850T2 (en) | 2008-05-07 | 2018-03-28 | Biomarin Pharm Inc | Lysosomal targeting peptides and their use |
| EP3679942A1 (en) | 2009-06-17 | 2020-07-15 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| WO2011044542A1 (en) | 2009-10-09 | 2011-04-14 | Armagen Technologies, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| IL291554B2 (en) | 2010-06-25 | 2024-02-01 | Shire Human Genetic Therapies | Administering therapeutic agents to the central nervous system |
| WO2011163652A2 (en) | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
| MX2013000320A (es) | 2010-06-25 | 2013-06-05 | Shire Human Genetic Therapies | Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa. |
| ME03649B (me) | 2010-06-25 | 2020-07-20 | Shire Human Genetic Therapies | Postupci i kompozicije za isporuku iduronat-2-sulfataze u cns |
| MX382443B (es) | 2010-06-25 | 2025-03-11 | Shire Human Genetic Therapies | Una formulación estable para usarse en el tratamiento de la enfermedad por leucodistrofia metacromática (mld). |
| PE20130589A1 (es) | 2010-06-25 | 2013-05-19 | Shire Human Genetic Therapies | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a |
| HK1200189A1 (en) * | 2011-12-01 | 2015-07-31 | 安吉奥开米公司 | Targeted lysosomal enzyme compounds |
| WO2013096899A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| US9687561B2 (en) | 2012-08-14 | 2017-06-27 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
| KR102521039B1 (ko) | 2012-11-27 | 2023-04-12 | 바이오마린 파머수티컬 인크. | 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들 |
| KR20150132332A (ko) | 2013-03-15 | 2015-11-25 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 저농도 항체 제형 |
| CA2943140A1 (en) | 2014-04-01 | 2015-10-08 | Swedish Orphan Biovitrum Ab (Publ) | Modified sulfamidase and production thereof |
| CN107921143B (zh) | 2015-06-15 | 2021-11-19 | 安吉奥开米公司 | 用于治疗软脑膜癌病的方法 |
| AU2017222620B2 (en) | 2016-02-24 | 2022-06-16 | Biomarin Pharmaceutical Inc. | Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof |
| US10874750B2 (en) | 2018-04-30 | 2020-12-29 | Amicus Therapeutics, Inc. | Gene therapy constructs and methods of use |
| WO2020077114A2 (en) | 2018-10-10 | 2020-04-16 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
| WO2020132452A1 (en) | 2018-12-20 | 2020-06-25 | Shire Human Genetic Therapies, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| AU6501390A (en) * | 1989-09-21 | 1991-04-18 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| US6472140B1 (en) * | 1997-09-05 | 2002-10-29 | The General Hospital Corporation | α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease. |
| IL158623A0 (en) * | 2001-04-30 | 2004-05-12 | Symbiontics Inc | Subcellular targeting of therapeutic proteins |
| AU2002362930A2 (en) * | 2001-10-16 | 2003-04-28 | Zystor Therapeutics, Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| AU2003237314B2 (en) * | 2002-05-29 | 2010-03-04 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
-
2002
- 2002-10-16 AU AU2002362930A patent/AU2002362930A2/en not_active Abandoned
- 2002-10-16 JP JP2003535542A patent/JP2005506340A/ja active Pending
- 2002-10-16 IL IL16135202A patent/IL161352A0/xx unknown
- 2002-10-16 CA CA002463473A patent/CA2463473A1/en not_active Abandoned
- 2002-10-16 WO PCT/US2002/032996 patent/WO2003032913A2/en not_active Ceased
- 2002-10-16 AU AU2002347910A patent/AU2002347910A1/en not_active Abandoned
- 2002-10-16 EP EP02801739A patent/EP1446007A4/en not_active Withdrawn
- 2002-10-16 WO PCT/US2002/032968 patent/WO2003032727A1/en not_active Ceased
-
2009
- 2009-06-16 JP JP2009143436A patent/JP2009203241A/ja active Pending
-
2010
- 2010-08-25 AU AU2010214643A patent/AU2010214643A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506340A5 (enExample) | ||
| WO2002043746A3 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
| JPH09504177A (ja) | Ｐｔｈ活性を有する化合物およびこれをコードする組み換えｄｎａベクター | |
| ES2327986T3 (es) | Liberacion intranuclear de compuestos dirigida por la proteina de choque termico de 70 kd. | |
| JPH02504279A (ja) | インスリン様成長因子１（ｉｇｆ‐１）または因子２（ｉｇｆ‐２）の類縁ペプチド | |
| DE602004024041D1 (de) | Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen | |
| JP2008526749A5 (enExample) | ||
| BG105461A (en) | Modified peptides as therapeutic agents | |
| WO1994023751A1 (de) | Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen | |
| AU665046B2 (en) | Molecules for iontophoretic delivery | |
| EP3565573B1 (en) | Pac1 receptor agonists (maxcaps) and uses thereof | |
| US20210290539A1 (en) | Engineered hemichannels, engineered vesicles, and uses thereof | |
| ZA200602000B (en) | Albumin-binding derivatives of therapeutic peptides | |
| RU2002130203A (ru) | Пептидные конъюгаты для доставки лекарственного средства | |
| CN1879888B (zh) | 透皮给药增强剂及其使用方法 | |
| US5843887A (en) | Compositions for delivery of polypeptides, and methods | |
| BR112020026267A2 (pt) | Lisinas e seus derivados resensibilizam novamente staphylococcus aureus e bactérias gram-positivas aos antibióticos | |
| CA2311648A1 (en) | Ifnar2/ifn complex | |
| F Nahhas et al. | Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics | |
| JP2007506713A (ja) | 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用 | |
| WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
| AU681891B2 (en) | Medical use of stem bromelain protease | |
| US20250257105A1 (en) | Icam-1 targeted fusion enzymes | |
| WO1999002120A8 (en) | Compositions and methods for reversibly increasing permeability of biomembranes | |
| KR101109163B1 (ko) | 타이로신-세린-발린(ｙｓｖ)을 포함하는 생물학적 활성펩티드 |